Tamoxifen (TAM) is a primary drug for treatment of estrogen receptor positive breast cancer. However, TAM resistance remains a serious threat to breast cancer patients and may be attributed to increased stemness of breast cancer. Here, we show that discs large homolog 5 (DLG5) expression is down-regulated in TAM-resis- 
cancer cells and TAM resistance has not been clarified. The Hippo signalling core kinases MST1/2 and downstream LATS1/2 phosphorylate YAP/TAZ, and promote their cytoplasmic sequestration and degradation. 13, 14 Inhibition of MST1/2 and LATS1/2 by DLG5 silencing promotes the nuclear localization of YAP. 10 Furthermore, TAZ, a YAP paralogue, is crucial for BCSCs. 15, 16 Accordingly, we have been suggested that DLG5 may regulate TAM sensitivity by changing TAZ expression and nuclear translocation to modulate the stemness of breast cancer cells.
In this study, we examined DLG5 expression in paired of TAMsensitive and resistant breast cancer tissues and employed TAM-sensitive and resistant ER + breast cancer cells to determine the effect of altered DLG5 expression on TAM sensitivity, apoptosis and stemness as well as TAZ expression. Furthermore, we tested the impact of TAZ silencing on the TAM sensitivity and stemness of TAM-resistant breast cancer cells. Our data indicated that down-regulated DLG5 expression increased the breast cancer stem cell-like characteristics by enhancing TAZ expression, contributing to TAM resistance in ER + breast cancer.
| MATERIALS AND METHODS

| Patients and tissue specimens
The Xi'an Jiaotong University. 8 
| Immunohistochemistry
The paraffin-embedded breast cancer tissue sections (4 μm) were deparaffinized, rehydrated and subjected to antigen retrieval in sodium citrate buffer. The sections were treated with 3% hydrogen peroxide to inactivate endogenous peroxidase and treated with 10% The signals were photographed using a microscope slide scanner (Leica MP, SCN400). The intensity of antibody staining in individual fields was semi-quantitatively analysed, as described previously. 
| Immunofluorescence
The different groups of cells were fixed with a 4% paraformaldehyde for 15 minutes at room temperature (RT) and permeabilized in 0.2% Triton X-100 in PBS for 10 minutes. After being blocked with 5% bovine serum albumin (BSA) and 10% horse sera in PBS 
| Flow cytometry analysis
The bottom panels) or expressed as the mean ± SD of each group from three separate experiments. **P < 0.01, ***P < 0.001 in ultralow attachment 6-well plates (Corning). The cells were exposed to half volume of fresh medium (500 μL) every 3 days. On day 10 after incubation, the formed mammospheres in individual wells were captured under a light microscope.
| Soft-agar assay
The clonogenicity of individual groups of cells was determined by soft-agar colony formation assay, as described previously. 17 Briefly, 
| Statistical analysis
Data are expressed as the mean ± standard deviation (SD). The difference between groups was analysed by Student's t test using GraphPad Prism Version 7.00. A P-value of <0.05 was considered statistically significant.
TAM-resistant breast cancer tissues and cells
The relationship between DLG5 expression and TAM resistance in ER + breast cancer was firstly analysed by a gene expression profile in the GEO database (GSE26459), which showed that DLG5 expression in the TAM-resistance MCF7 cells was significantly lower than that in the TAM-sensitive MCF7 cells (P < 0.01, Figure 1A ). Immunohistochemistry analysis of nine paired of TAM resistant and sensitive breast cancer tissues indicated that while higher levels of DLG5 expression were detected in adjacent tissues the levels of DLG5 expression in the TAM-resistant breast cancer tissues were lower than that in the TAMsensitive breast cancer tissues in this population ( Figure 1B and C, Table 1 ). Similarly, the relative levels of DLG5 mRNA transcripts and protein expression in the TAM-resistant MCF7-TamR cells were significantly lower than that in the TAM-sensitive MCF-7 cells, but higher than that in the high TAM-resistant LCC2 cells ( Figure 1D -E). Such data indicated that down-regulated DLG5 expression was associated with TAM resistance in breast cancer. 3.4 | DLG5 suppresses the breast cancer stem celllike characteristics to restore TAM sensitivity by inhibiting TAZ expression and nuclear translocation
Given that the Hippo transducer TAZ is required for sustained selfrenewal of BCSCs, 16 we analysed TAZ expression in the gene expression profile from the GEO database (GSE26459) and our 
| DISCUSSION
TAM has been widely used for treatment of ER + breast cancers in the clinic. 20 However, TAM resistance is a huge challenge for clinical practice, and promotes breast cancer metastasis and death. 21, 22 Our previous studies and those of others have shown that DLG5 acts as a tumour suppressor in breast cancer, and its expression is up-regulated in Luminal type, but not basal-like, breast cancer.
10,11
DLG5 is a primary target of progesterone receptor 23 and DLG5
expression is positively correlated with ER and PR expression in breast cancers. 10 Loss of DLG5 expression induces EMT and disrupts epithelial cell polarity, which are associated with altered expression of cell polarity proteins, such as Scribble, ZO1, E-cadherin and N-cadherin and their mislocalization. 10 Furthermore, (f) endocrine adaptation (just in a minority of patients) 26, 27 In additional, increased stemness and cancer stem cell-like characteristics can contribute to drug resistance. 
